7,640.25

+26.25

+0.34%

52,016.00

+98.00

+0.19%

28,746.75

+212.75

+0.75%

Russell 2000 Futures

2,832.90

+11.60

+0.41%

4.9290

-0.0600

-1.20%

19.42

0.00

0.00%

3,902.10

+3.20

+0.08%

78,023.25

-86.99

-0.11%

Crude Oil Dec 26

100.31

-3.81

-3.66%

US Private Equity

10,850.63

-82.20

-0.75%

TSXV - Delayed Quote CAD

Hydreight Technologies Inc. (NURS.V)

3.1300 -0.4200 (-11.83%)

At close: October 30 at 3:59:58 PM EDT

Loading Chart for NURS.V

Chart Range Bar

Interval:

In partnership with ChartIQ

Hydreight Highlights U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Technology

Hydreight Highlights U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Technology

Hydreight Highlights U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Technology

Hydreight Highlights U.S. Patent Allowance for Insu Therapeutics' Needle-Free Insulin and GLP-1 Delivery Technology

Hydreight Technologies Inc (HYDTF) (Q2 2026) Earnings Call Highlights: Record Revenue Surges ...

Hydreight Technologies Inc (HYDTF) (Q2 2026) Earnings Call Highlights: Record Revenue Surges ...

Hydreight Reports Record Q2 2026 Revenue of $28.0 Million, Net Income of $2.5 Million and Adjusted EBITDA of $3.2 Million

Hydreight Reports Record Q2 2026 Revenue of $28.0 Million, Net Income of $2.5 Million and Adjusted EBITDA of $3.2 Million

Hydreight Reports Record Q2 2026 Revenue of $28.0 Million, Net Income of $2.5 Million and Adjusted EBITDA of $3.2 Million

Hydreight Reports Record Q2 2026 Revenue of $28.0 Million, Net Income of $2.5 Million and Adjusted EBITDA of $3.2 Million

Hydreight to Participate in Canaccord Genuity's 46th Annual Growth Conference in Boston

Hydreight to Participate in Canaccord Genuity's 46th Annual Growth Conference in Boston

Hydreight to Participate in Canaccord Genuity's 46th Annual Growth Conference in Boston

Hydreight to Participate in Canaccord Genuity's 46th Annual Growth Conference in Boston

Victory Square Provides Update on Hydreight and Healthcare Investments Following FDA Advisory Committee Recommendations on Peptide-Related Bulk Drug Substances

Victory Square Provides Update on Hydreight and Healthcare Investments Following FDA Advisory Committee Recommendations on Peptide-Related Bulk Drug Substances

Hydreight Provides Business Update on its Peptide Healthcare Platform Following Recent FDA Advisory Committee Recommendations

Hydreight Provides Business Update on its Peptide Healthcare Platform Following Recent FDA Advisory Committee Recommendations

Hydreight Technologies Inc (HYDTF) Q1 2026 Earnings Call Highlights: Record Revenue and ...

Hydreight Technologies Inc (HYDTF) Q1 2026 Earnings Call Highlights: Record Revenue and ...

Hydreight Announces Refiling of Interim Financial Statements

Hydreight Announces Refiling of Interim Financial Statements

Mobilize your Website

View Site in Mobile | Classic

Share by: